FDA Monograph vs CPNP: Dual-Market Filing Gaps

Map the FDA CPNP whitening compliance gaps — classification triggers, GMP document sets, and importer-of-record obligations — before your first dual-market shipment.

FDA CPNP Whitening Compliance Is Not a Single Filing Problem

Importers sourcing one whitening product line for simultaneous US and EU distribution routinely underestimate how different the two regulatory frameworks are at their foundations. FDA CPNP whitening compliance is not a matter of submitting two parallel forms — it is a matter of navigating two entirely separate classification systems, each with its own definition of what the product is before any documentation is filed. Getting that classification wrong upstream causes detained shipments, clearance failures, and reformulation costs that could have been avoided at the sourcing stage.

This article maps the specific filing divergences that create those failures — classification triggers, GMP document sets, and importer-of-record obligations — so procurement and regulatory teams can identify gaps before the first container leaves the manufacturer.

One Product Rarely Qualifies as a Cosmetic on Both Sides of the Atlantic

The classification trigger differs in each jurisdiction, and it starts with the claim, not the ingredient. In the United States, a whitening product that makes a therapeutic claim — or contains an active ingredient listed in an FDA OTC monograph — is regulated as a drug. In the EU, the same product may qualify as a cosmetic under Regulation 1223/2009, provided it stays within permitted ingredient limits and carries no therapeutic claims.

A single SKU formulated for EU cosmetic notification can simultaneously require OTC drug compliance in the US. The product has not changed. The regulatory category has. Importers who treat CPNP notification as equivalent to FDA clearance are conflating two systems that do not recognize each other.

A practical example: a whitening gel containing hydrogen peroxide at a concentration permitted under EU cosmetic rules may still trigger OTC drug classification in the US if the labeling references any effect beyond surface stain removal. That single label line can convert a cosmetic import into an unapproved drug shipment at the US border.

FDA OTC Monograph: What the Importer of Record Actually Owns

Under the OTC Monograph Reform framework established by the CARES Act and codified in section 505G of the Federal Food, Drug, and Cosmetic Act, a whitening product can be marketed in the US without a full New Drug Application — but only when it conforms to every condition of the applicable monograph. That means permitted active ingredients, permitted concentrations, permitted uses, required labeling language, and applicable testing requirements.

The importer of record is not filing a notification in the way EU importers file with CPNP. The importer assumes responsibility for ensuring the product already meets monograph conditions before it enters commerce. There is no pre-market approval window or FDA acknowledgment. The obligation is to be in compliance, not to receive permission.

In practice, the importer of record must hold:

Documentation confirming active ingredient identity and concentration against monograph-permitted levels
Labeling reviewed against required statements, warnings, and directions in the applicable monograph
Manufacturing records demonstrating compliance with 21 CFR 330.1 general conditions
Evidence that no non-monograph active ingredients are present in the formulation

FDA's OTC Monograph M022 for Oral Healthcare Drug Products and M021 for Anticaries Drug Products define the ingredient and condition framework for oral-care claims. If a supplier's product does not map cleanly to those conditions, the importer has no compliant pathway under the monograph system — and no EU filing substitutes for that gap.

CPNP Notification: Responsible Person Obligations That Importers Underestimate

Under EU Regulation 1223/2009, every cosmetic product placed on the EU market must be notified through the Cosmetic Products Notification Portal before it is made available. The notification is submitted by the Responsible Person — a legal entity established within the EU that assumes liability for the product's compliance with the Regulation.

For non-EU manufacturers supplying importers who then sell into EU markets, the importer typically becomes the Responsible Person by default. That designation carries obligations well beyond portal data entry.

The Responsible Person must maintain a Product Information File that includes:

A cosmetic product safety report signed by a qualified safety assessor
A product description and manufacturing method
Evidence of the claimed effect — efficacy substantiation
Data on animal testing status
A complete ingredient list in INCI nomenclature

One CPNP notification covers the entire EU single market — no separate filings per member state are required. However, the Responsible Person designation means any enforcement action in any member state falls on that entity. Importers who treat CPNP as a lightweight administrative step frequently discover that the safety report alone requires significant investment in toxicological assessment.

GMP Document Sets: Where US and EU Requirements Diverge

Both markets require GMP compliance, but the reference standards, audit expectations, and document formats differ in ways that create real friction when a supplier is set up for only one market.

In the US, OTC drug products — including monograph-compliant whitening products — must be manufactured under 21 CFR Part 211 Current Good Manufacturing Practice regulations. These are drug GMPs. Documentation requirements include batch records, stability data, in-process testing, and equipment qualification at a level substantially more rigorous than cosmetic manufacturing standards.

In the EU, cosmetic products must be manufactured in accordance with ISO 22716. ISO 22716 is comprehensive, but it is a cosmetic standard — not a pharmaceutical one. A supplier audited and certified to ISO 22716 has not demonstrated compliance with 21 CFR Part 211.

Requirement	US — OTC Drug / 21 CFR 211	EU — Cosmetic / ISO 22716
Batch manufacturing records	Required, drug-grade detail	Required, cosmetic-grade detail
Stability testing	ICH-aligned, pharmaceutical protocols	Adequate to support shelf-life claim
In-process controls	Formally documented and validated	Defined but less prescriptive
Audit standard	FDA inspection / 483 observations	ISO 22716 audit / Responsible Person review

A supplier presenting only an ISO 22716 certificate cannot satisfy US OTC drug GMP requirements. An importer who accepts that certificate as dual-market GMP evidence is holding an incomplete document set for the US side of the business.

Active Concentration Ceilings Force Separate Product Variants

Concentration limits for whitening actives are not harmonized across the two markets, and permitted levels in each jurisdiction reflect different regulatory philosophies about what the product fundamentally is.

In the EU, hydrogen peroxide concentrations in cosmetic whitening products are subject to limits defined in Annex III of Regulation 1223/2009. Products intended for professional use by dental practitioners operate under different conditions than consumer-facing products. Formulations exceeding those limits cannot be notified through CPNP as cosmetics — they require a separate regulatory pathway.

In the US, the OTC monograph framework governs permitted active ingredients and their concentrations for drug-classified products. A product that falls outside monograph-permitted conditions cannot be marketed under the monograph system without an approved NDA.

The practical consequence: a single formulation is rarely optimized for both markets simultaneously. Importers sourcing one SKU for dual distribution frequently discover they need at least two product variants — one formulated and labeled for EU cosmetic compliance, one formulated and labeled for US OTC drug compliance. Attempting to satisfy both markets with one formulation and one label almost always means compromising compliance in at least one jurisdiction.

Dual-Market FDA CPNP Whitening Compliance Checklist

Work through this sequence before committing to a supplier or placing an initial order. The checklist is structured by filing stage, not alphabetical order.

Classification and Claim Audit

Confirm the active ingredient against FDA monograph-permitted actives under M022 and M021
Confirm the active concentration against EU Annex III limits for cosmetic classification
Review all intended label claims for both markets — flag any language that could trigger drug classification in the US
Determine whether separate SKUs are required for each market before finalizing the formulation brief

US Filing Readiness

Obtain full 21 CFR Part 211 GMP documentation from the supplier
Assign and document importer-of-record responsibilities in the supply agreement
Review labeling against monograph-required statements, warnings, and directions
Confirm no non-monograph actives are present — obtain a certificate of analysis for each batch

EU Filing Readiness

Identify or appoint a Responsible Person established within the EU
Commission a cosmetic product safety report from a qualified safety assessor before submission
Compile the full Product Information File prior to CPNP notification
Confirm ISO 22716 GMP certification from the supplier
Verify INCI ingredient list accuracy for the CPNP submission portal

Red Flags That Signal a Single-Market Supplier Setup

Most whitening manufacturers are optimized for one primary regulatory market. The documentation they provide by default reflects that orientation. The following signals indicate a supplier has not been configured for dual-market compliance.

ISO 22716 only, no 21 CFR Part 211 documentation. The supplier can support EU cosmetic filing but cannot provide drug-grade GMP records for US OTC compliance. This is the most common document gap in dual-market sourcing engagements.

A single label template described as globally compliant. US OTC drug labeling and EU cosmetic labeling carry different mandatory elements that cannot be reconciled in one layout. A supplier offering one universal label has not addressed both markets.

CPNP notification history presented as regulatory clearance. Some suppliers reference existing EU notifications as evidence of broad compliance. CPNP notification is not FDA clearance. Treating it as equivalent indicates the supplier does not understand the US pathway — and that gap becomes the importer's liability.

Stability data formatted for cosmetic shelf-life only. US OTC drug products require stability data aligned with pharmaceutical protocols. Cosmetic stability studies are not interchangeable with drug stability data for FDA purposes.

No importer-of-record language in the supply agreement. A supplier experienced in dual-market distribution addresses importer-of-record obligations contractually. Absence of that language indicates the supplier has no dual-market distribution experience — and no established framework for sharing compliance accountability.

Private-label brand owners co-developing a whitening line for both markets should raise each of these points during supplier qualification, not after the first shipment. The cost of resolving classification errors post-shipment — reformulation, relabeling, detained inventory — is significantly higher than the cost of a structured pre-sourcing audit. For an overview of formulation options engineered for multi-market private-label programs, see the WhiteningBright product range.

References

Disclaimer

This article is for general informational purposes only and does not constitute sourcing, legal, or regulatory advice. Always conduct your own due diligence and consult qualified legal or compliance professionals before making purchasing or compliance decisions. WhiteningBright makes no warranties as to the completeness or accuracy of the information, and any reliance is at your own risk.